Global business process and operations company Genpact is to acquire Pharmalink Consulting. The acquisition will complement Genpact’s portfolio of life sciences services and add consulting, outsourcing and operations to its capabilities.
The deal also significantly expands Genpact’s capabilities in supporting the life sciences research and development functions, including regulatory strategy, filing submissions, complex compliance services and the management of post-licensing activities.
Pharmalink’s specialized domain expertise, speed, responsiveness and ability to scale have made it a leading provider for sustainable outsourcing of regulatory affairs services. Its clients include nearly all of the 20 largest global life sciences companies.
NV ‘Tiger’ Tygarajan, Genpact’s President and CEO, said that the acquisition fits in exactly with the company’s strategy to invest in solutions in growth areas in specific verticals such as life sciences. He added: “In an industry that’s undergoing intense transformation, adding Pharmalink’s combination of talent, proves expertise and domain knowledge to Genpact’s portfolio will allow us to better serve out life sciences clients.
“Genpact will bring the global scale, process excellence, analytical insights and technology needed to further enhance our outsourcing services offering demanded by the market,” said Peter Griffin, Chairman, Pharmalink Consulting. “This combination will allow us to deliver more end-to-end regulatory affairs solutions based on Genpact’s proprietary Smart Enterprise Processes (SEPSM) methodology.”
Gary Charbonneau, Vice President of Global Regulatory Affairs at Allergan added: “The combination of Genpact and Pharmalink is very exciting not just for me as a client, but for the industry at large. To have the deep experience and reputation of Pharmalink within the Regulatory Affairs arena allied to the scale and process excellence of Genpact is a compelling proposition.”
As part of the transaction, Pharmalink’s employees based in the US, the UK, India, Ireland and Puerto Rico will become part of Genpact’s life sciences vertical.